CLL/SLL

TRANSCEND CLL 004 study

L: English

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Tanya Siddiqi, City of Hope Comprehensive Cancer Center, Duarte, US. In this video, Tanya Siddiqi discusses the TRANSCEND CLL 004 study.

Tanya Siddiqi describes findings from the TRANSCEND CLL 004 phase I/II study of a CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), in patients with relapsed or refractory chronic lymphocytic leukemia